PVLA
Palvella Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$157.24
+1.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 25.9M |
| Cost of Revenue | — | — | — | — | 2.8M |
| Gross Profit | — | — | — | — | 23.1M |
| Operating Expenses | |||||
| R&D Expense | 35.5M | 22.8M | 8.2M | 8.8M | 50.2M |
| SG&A Expense | 22.3M | 15.8M | 5.9M | 3.1M | 16.4M |
| General & Admin Expense | 22.3M | 15.8M | 5.9M | 3.1M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 57.7M | 38.6M | 14.1M | 11.9M | 66.6M |
| Cost and Expenses | 57.7M | 38.6M | 14.1M | 11.9M | 69.4M |
| Operating Income (EBIT) | (57.7M) | (38.6M) | (14.1M) | (11.9M) | (43.5M) |
| Non-Operating | |||||
| Interest Income | 4.2M | 2.6M | 642.0K | 6.3M | 721.0K |
| Interest Expense | 7.6M | 5.8M | 4.3M | — | — |
| Net Interest Income | (3.4M) | (3.2M) | (3.7M) | 6.3M | 721.0K |
| Other Non-Op Income/Expense | (4.0M) | (3.1M) | (3.3M) | 30.6M | 10.2M |
| Non-Operating Income (excl Interest) | 2.4M | (2.7M) | (978.0K) | (30.6M) | (10.2M) |
| EBT (Pre-Tax Income) | (61.7M) | (41.7M) | (17.4M) | 18.7M | (33.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (61.7M) | (41.7M) | (17.4M) | 18.7M | (33.3M) |
| Earnings from Cont. Ops | (61.7M) | (41.7M) | (17.4M) | 18.7M | (33.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (61.7M) | (41.7M) | (17.4M) | 17.9M | (33.3M) |
| Per Share | |||||
| Basic EPS | ($4.83) | ($3.71) | ($7.83) | $14.74 | ($29.61) |
| Diluted EPS | ($4.83) | ($3.71) | ($7.83) | $14.74 | ($29.61) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $27.84 |
| Shares | |||||
| Basic Shares Outstanding | 14.4M | 11.3M | 2.2M | 1.3M | 930352 |
| Diluted Shares Outstanding | 14.4M | 11.3M | 2.2M | 1.3M | 930352 |
| Profitability Metrics | |||||
| EBITDA | (50.0M) | (35.9M) | (13.1M) | 18.7M | (30.5M) |
| D&A | 10.2M | — | — | — | 2.8M |
| EBIT | (60.2M) | (35.9M) | (13.1M) | 18.7M | (33.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026